News - Medivation

Filter

Current filters:

Medivation

Popular Filters

1 to 25 of 27 results

Promising emerging agents for triple negative breast cancer

08-04-2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

Astellas files for wider use of prostate cancer drug Xtandi in Europe

03-04-2014

Japanese drug major Astellas Pharma has submitted a variation to amend the Marketing Authorization Application…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalRegulationXtandi

Astellas’ Xtandi cleared in Japan for prostate cancer treatment

24-03-2014

Japanese drug major Astellas Pharma has obtained the marketing approval in Japan of its oral androgen…

Asia-PacificAstellas PharmaJapanMedivationOncologyPharmaceuticalRegulationXtandi

Astellas and Medivation file sNDA for new Xtandi indication

Astellas and Medivation file sNDA for new Xtandi indication

18-03-2014

Japanese drug major Astellas Pharma and US partner Medivation have filed a supplemental New Drug Application…

Astellas PharmaMedivationNorth AmericaOncologyPharmaceuticalRegulationUSAXtandi

IQWiG now finds “major” benefit for Xtandi

24-02-2014

In an early benefit assessment under Germany’s Act on the Reform of the Market for Medicinal Products…

Astellas PharmaGermanyMedivationNorthern EuropeOncologyPharmaceuticalPricingRegulationXtandi

Medivation and Astellas announce final results of Phase III enzalutamide trial in prostate cancer

Medivation and Astellas announce final results of Phase III enzalutamide trial in prostate cancer

29-01-2014

Medivation and Japanese drug major Astellas Pharma have announced final results on the primary and secondary…

Astellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchUSAXtandi

IQWiG finds hint of added benefit for Xtandi in prostate cancer

IQWiG finds hint of added benefit for Xtandi in prostate cancer

09-12-2013

In an early benefit assessment under the Act on the German Reform of the Market for Medicinal Products…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalPricingRegulationXtandi

Medivation and Astellas reveal positive Phase III results for prostate cancer drug

Medivation and Astellas reveal positive Phase III results for prostate cancer drug

23-10-2013

Medivation and Japanese drug major Astellas Pharma have announced positive results from the Phase III…

Asia-PacificAstellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchXtandi

Astellas and Medivation's Xtandi approved in EU for advanced prostate cancer

24-06-2013

Japanese drug major Astellas Pharma (TYO: 4503) European subsidiary today (June 24) received approval…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalRegulationXtandi

Astellas and Medivation file for approval of enzalutamide in Japan

24-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted an application for marketing approval of…

Asia-PacificAstellas PharmaenzalutamideMedivationOncologyPharmaceuticalRegulationXtandi

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Medivation and Astellas debut Xtandi in USA

14-09-2012

USA-based Medivation (Nasdaq: MDVN) and Japanese partner Astellas Pharma (TSE: 4503) yesterday announced…

Astellas PharmaenzalutamideMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalXtandi

FDA backs Medivation and Astellas' prostate cancer drug Xtandi

03-09-2012

USA-based Medivation (Nasdaq: MDVN and Japanese drug major Astellas Pharma (TYO: 4503) say that the US…

Astellas PharmaBiotechnologyenzalutamideMedivationNorth AmericaOncologyPharmaceuticalRegulationXtandi

Phase III study shows enzalutamide offers significant benefit in prostate cancer

17-08-2012

USA-based Medivation (Nasdaq: MDVN) and Japanese drug major Astellas (TSE: 4503) has announced the publication…

Astellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearch

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close

07-08-2012

The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

Astellas submits prostate cancer drug for EU approval

28-06-2012

Japanese drug major Astellas Pharma (TYO: 4503) yesterday filed a marketing authorization application…

Astellas PharmaenzalutamideEuropeMedivationOncologyPharmaceuticalRegulation

Expanded Access Program for enzalutamide agreed with US FDA

30-05-2012

The US Food and Drug Administration agreed that Medivation (Nasdaq: MDVN) and Japanese drug major Astellas…

Astellas PharmaBiotechnologyenzalutamideMDV3100MedivationNorth AmericaOncologyPharmaceuticalRegulation

Medivation files NDA for prostate cancer drug enzalutamide

23-05-2012

US drug developer Medivation (Nasdaq: MDVN) says it has submitted a New Drug Application to the US Food…

Astellas PharmaenzalutamideMDV3100MedivationNorth AmericaOncologyPharmaceuticalRegulation

Pfizer, Medivation finally pull plug on Dimebon

18-01-2012

Following previous disappointing clinical trials results for their potential Alzheimer’s drug candidate,…

DimebonLicensingMedivationNeurologicalPfizerPharmaceuticalResearch

1 to 25 of 27 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top